At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02509 QYUNS-B
Closed 07-10 16:08:36
15.290
+0.210
+1.39%
High15.800Low15.200Vol315.40K
Open15.570D1 Closing15.080Amplitude3.98%
Mkt Cap3.41BTradable Cap3.41BTotal Shares223.00M
T/O4.90MT/O Rate0.14%Tradable Shares223.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
QYUNS-B (02509) Repurchases 3,000 Shares for Approximately HK$45,200 on July 9
Stock News  ·  07-09 18:26
QYUNS-B (02509) Repurchases 3,000 Shares for Approximately HK$45,200 on July 9
Qyuns Therapeutics Files HKEX Next-day Disclosure Return on Share Repurchase for Treasury Shares at HKD 15.08
Reuters  ·  07-09 18:21
Qyuns Therapeutics Files HKEX Next-day Disclosure Return on Share Repurchase for Treasury Shares at HKD 15.08
Qyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each
Bulletin Express  ·  07-08 18:45
Qyuns Therapeutics Executes Minor Share Buyback; Adds 600 H-Shares to Treasury at HKD 15.70 Each
QYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million
Bulletin Express  ·  07-07
QYUNS-B Buys Back 8,000 H Shares, Boosts Treasury Stock to 3.70 Million
Qyuns Therapeutics Files HKEX Next-day Disclosure Return After Share Repurchase for Cancellation
Reuters  ·  07-07
Qyuns Therapeutics Files HKEX Next-day Disclosure Return After Share Repurchase for Cancellation
QYuns-B Shares Surge Over 8% Following CLD-423 Injection Clinical Trial Approval and Progress in Overseas Licensing
Stock News  ·  07-06
QYuns-B Shares Surge Over 8% Following CLD-423 Injection Clinical Trial Approval and Progress in Overseas Licensing
Qyuns Therapeutics Executes HKD 45,812 Share Buyback, Lifts Treasury Stock to 3.69 Million Shares
Bulletin Express  ·  06-30
Qyuns Therapeutics Executes HKD 45,812 Share Buyback, Lifts Treasury Stock to 3.69 Million Shares
QYUNS-B Repurchases Shares for Approximately HK$45,800
Stock News  ·  06-30
QYUNS-B Repurchases Shares for Approximately HK$45,800
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Repurchase for Treasury Shares
Reuters  ·  06-30
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Repurchase for Treasury Shares
QYUNS-B Shares Surge Over 8% on Plan to Acquire Remaining Stake in CMC Subsidiary to Advance Core Drug Filings
Stock News  ·  06-29
QYUNS-B Shares Surge Over 8% on Plan to Acquire Remaining Stake in CMC Subsidiary to Advance Core Drug Filings
Qyuns Therapeutics to Acquire Remaining 34.00% Stake in Cellularforce for RMB 86.02 Million, Moving to Full Ownership
Bulletin Express  ·  06-26
Qyuns Therapeutics to Acquire Remaining 34.00% Stake in Cellularforce for RMB 86.02 Million, Moving to Full Ownership
Qyuns Therapeutics Buys Remaining 34% Stake in Cellularforce for RMB 86.02 Million
Reuters  ·  06-26
Qyuns Therapeutics Buys Remaining 34% Stake in Cellularforce for RMB 86.02 Million
Qyuns Therapeutics Co - Saifu Juli to Buy 34% of Cellularforce for Rmb86.02 Mln
THOMSON REUTERS  ·  06-26
Qyuns Therapeutics Co - Saifu Juli to Buy 34% of Cellularforce for Rmb86.02 Mln
QYUNS-B (02509) Allocates HK$65,600 for Share Buyback on June 26
Stock News  ·  06-26
QYUNS-B (02509) Allocates HK$65,600 for Share Buyback on June 26
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Repurchase at HKD 13.67
Reuters  ·  06-26
Qyuns Therapeutics Files HKEX Next-day Disclosure Reporting Share Repurchase at HKD 13.67
QYUNS-B (02509) Allocates HK$175,000 for Share Buyback on June 22
Stock News  ·  06-22
QYUNS-B (02509) Allocates HK$175,000 for Share Buyback on June 22
Qyuns Therapeutics files HKEX next-day disclosure return on share repurchase at HKD 13.4-13.99
Reuters  ·  06-22
Qyuns Therapeutics files HKEX next-day disclosure return on share repurchase at HKD 13.4-13.99
QYUNS-B (02509) Invests HK$369,500 in Share Buyback on June 17
Stock News  ·  06-17
QYUNS-B (02509) Invests HK$369,500 in Share Buyback on June 17
Qyuns Therapeutics files HKEX next-day disclosure, reports share repurchase for treasury shares at HKD 14.64
Reuters  ·  06-16
Qyuns Therapeutics files HKEX next-day disclosure, reports share repurchase for treasury shares at HKD 14.64
QYUNS-B (02509) Allocates HK$629,800 for Share Buyback on June 15
Stock News  ·  06-15
QYUNS-B (02509) Allocates HK$629,800 for Share Buyback on June 15

Introduction

Company Name.
QYUNS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Qyuns Therapeutics Co Ltd is a China-based company principally engaged in the research and development, manufacturing and commercialisation of biologic therapies for autoimmune and allergic diseases. The Company focuses on dermatology, respiratory, gastroenterology and rheumatology diseases. The Company's products include SAILEXIN, Oturkibart, and Crusekitug. The Company conducts its businesses in domestic and overseas markets.
Issue price:
--